MYDA Advisors’s Enliven Therapeutics ELVN Stock Holding History

MYDA Advisors’s Portfolio ELVN Stock Details ELVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-10,000	Closed	-$91K	–	94
2022 Q3	$91K	Buy	+10,000	New	+$59K	0.04%	138

Other funds holding ELVN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

MYDA Advisors's ELVN Position: Q4 2022 in Review

MYDA Advisors sold out of Enliven Therapeutics (ELVN) in Q4 2022, closing a stake of 10,000 shares — an estimated $91K sold.

MYDA Advisors first reported a position in ELVN in Q3 2022 and held it in 1 quarter. The position peaked at $91K in Q3 2022. 36 funds tracked by Wall St. Rank hold ELVN as of Q4 2022.

MYDA Advisors reported no remaining Enliven Therapeutics position as of Q4 2022 after selling out during the quarter.
MYDA Advisors sold 10,000 Enliven Therapeutics shares in Q4 2022, an estimated $91K.
MYDA Advisors first reported a position in Enliven Therapeutics in Q3 2022 and held it in 1 quarter.
MYDA Advisors's Enliven Therapeutics position peaked at $91K in Q3 2022.
36 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q4 2022.

Based on MYDA Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.